Amsterdam, February 3, 2014 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced a new concept methods journal: MethodsX.
Researchers spend up to 80% of their time customizing and tweaking existing methods to make them better fit their specific research setting. By providing a home for these often unpublished records, MethodsX allows researchers to receive public credit and citations for that work without spending time writing a full, traditional research article.
"This is a new approach to scientific publishing. We believe that MethodsX will dramatically change how researchers assess and build on recognized techniques, saving the scientific community valuable time and money," commented Irene Kanter-Schlifke, Executive Publisher at Elsevier.
As an online-only, open access journal, MethodsX publishes papers in all disciplines of experimental research, from Life Sciences to Health Sciences to Physical Sciences.
A paper published in MethodsX includes:
"MethodsX fulfills a real need for researchers to publish their work on developing methods so that they can easily be found by others," said Gregory J. Tsongalis, Advising Editor for MethodsX and Professor of Pathology at the Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth. "It's also good for researchers as they can get recognized for their time and effort."
The first articles are now freely available online on ScienceDirect: http://www.sciencedirect.com/science/article/pii/S2215016114000028
For more information or to submit an article, visit http://www.elsevier.com/locate/MethodsX
About Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as 82 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 2467
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.